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Abstract
pVHL, product of von Hippel-Lindau (VHL) tumor suppressor gene, functions as the substrate recognition component of an
E3-ubiquitin ligase that targets proteins for ubiquitination and proteasomal degradation. Hypoxia-inducible factor a (HIFa)
is the well-known substrate of pVHL. Besides HIFa, pVHL also binds to many other proteins and has multiple functions. In
this manuscript, we report that the nuclear clusterin (nCLU) is a target of pVHL. We found that pVHL had a direct interaction
with nCLU. nCLU bound to pVHL at pVHL’s b domain, the site for recognition of substrate, indicating that nCLU might be a
substrate of pVHL. Interestingly, pVHL bound to nCLU but did not lead to nCLU destruction. Further studies indicated that
pVHL mediated K63-linked ubiquitination of nCLU and promoted nCLU nuclear translocation. In summary, our results
disclose a novel function of pVHL that mediates K63-linked ubiquitination and identify nCLU as a new target of pVHL.
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Introduction
pVHL, product of von Hippel-Lindau (VHL) tumor suppressor
gene, acts as a multipurpose adaptor protein that controls a diverse
array of gene expression programs, as well as extracellular matrix
assembly and microtubule-based processes by linking various
target proteins to appropriate enzymatic activities [1]. Germline
mutations in VHL can be found in patients with VHL disease, a
familial tumor syndrome characterized by the development of
highly vascularized tumors in multiple organs [2,3]. Major clinical
manifestation of VHL disease include hemangioblastomas of the
retina and central nervous system, renal cysts and clear cell renal
cell carcinoma, pancreatic cysts and tumors, as well as pheochro-
mocytomas [2,3]. VHL is also mutated in the majority of sporadic
clear cell renal cell carcinoma. pVHL forms a multi-protein
complex that contained elongin B, elongin C, Cul2, and Rbx1 and
functions as the substrate recognition component of an E3-
ubiquitin ligase complex that targets proteins for degradation [4–
6]. The best-understood function of pVHL relates to its role that
targets the alpha subunit of hypoxia-inducible factor (HIFa) for
destruction [3,7]. pVHL binds to hydroxylated HIFa and
mediates HIFa ubiquitination and proteasomal degradation
[8,9]. The pVHL-mediated degradation of HIFa is involved in
tumor progression as well as oxygen sensing [10]. Besides HIFa,
pVHL has been found to bind to a dozen different proteins and
mediates other biological processes [1,3,11]. pVHL has a direct
interaction with atypical protein kinase C and inhibits its activities
[12]. pVHL binds to hydroxylated a-chain of collagen IV [13] and
reacts with fibronectin [14]. pVHL is also involved in regulation of
NF-kB [15] and Wnt signaling [16].
Clusterin (CLU) is an enigmatic glycoprotein with a nearly
ubiquitous tissue distribution, involved in many biological
processes [17]. CLU is also believed to be involved in many
pathological states including cancer [18]. It may promote cell
survival or induce cell apoptosis, depending on its different
isoforms. [18,19]. The secreted form of CLU (sCLU) is present in
almost all physiological fluids [20] and is considered to be a
survival factor [21]. In addition to sCLU, a nuclear form of CLU
(nCLU) exists. And nCLU has been found to trigger cell death in a
few systems [22].
Previous study demonstrated that expression of sCLU was
attenuated in cells lacking wild-type pVHL [23]. However, the
effect of pVHL on nCLU is unknown. We found in our work that
pVHL bound to nCLU but did not target it for destruction.
Interestingly, we found that pVHL mediated K63-linked ubiqui-
tination of nCLU and promoted its nuclear translocation. Our
results reveal a novel function of pVHL that mediates K63-linked
ubiquitination and identify nCLU as a new target of pVHL.
Materials and Methods
Cell culture and reagents
Human embryonic kidney 293T cells and human cervix cancer
Hela cells were cultured in DMEM with 10% serum, penicillin
(100 U/mL), and streptoMycin (100 mg/mL). Human colon
cancer HCT116 cells were cultured in McCoy’s 5A media
(M5A) with 10% serum, penicillin (100 U/mL), and streptoMycin
(100 mg/mL). pVHL antibody was from BD Biosciences (Bedford,
MA). nCLU (B5), HA, Myc and His antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibody against Ub(K63)
(BML-PW0600-0025) was from Enzo Life Sciences (Farmingdale,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35848NY). Beta-actin and a-tubulin antibodies, cycloheximide and
MG132 were from Sigma (St. Louis, MO).
Construction of vectors
nCLU was constructed by polymerase chain reaction (PCR) and
cloned into pcDNA3.0 vector (with HA tag) or pcDNA3.1 vector
(with Myc tag). Deletion forms of VHL were cloned into
pCDNA3.1 vector or into pET-28a Vector (with His epitope).
R-VHL was constructed through inserting VHL into pDsRed-
Monomer-N1 vector between Xho I and Hind III. Glutathione S-
transferase (GST)-nCLU fusion proteins were constructed by
inserting PCR-generated DNA fragments encoding nCLU into
pGEX4T1. E. coli BL21-Gold(DE3)pLysS cells were transformed
with pGEX4T1 or pET28a expression vectors and treated with
0.1 mmol/L of isopropyl-D-thiogalactoside for 4 h. Ubiquitin was
constructed by PCR and various mutated ubiquitin constructs
were generated by site-directed mutagenesis. The diagram of
ubiquitin mutants is as follows.
61 1 2 7 2 93 34 8 6 3
Ub ----K-----K----K----K------K------K-----K---
Ub(K48) ----R-----R----R----R-----R------K-----R---
Ub(K63) ----R-----R----R----R-----R------R-----K---
Ub(K63R) ----K-----K----K----K------K------K-----R---
Ub(K48R) ----K-----K----K----K------K------R-----K---
Immuno-staining of cells
The cells, grown on glass coverslip were washed and fixed with
4% formaldehyde for 20 minutes, followed by permeabilization
with 0.1% Triton X-100. After wash, the coverslips were blocked
in 3% BSA for 1 h, followed by the incubation with primary
antibody at 4uC overnight. After wash, the coverslips were
incubated with fluorescence dye-conjugated secondary antibody
for 30 min. Finally, the cells were stained with DAPI in the dark
for 3 min. The stained cells were mounted and observed in A Zeiss
LSM 510 META (Axiovert 200) microscope.
Nuclear protein extraction
Cells were washed and suspended in 100 mL of buffer A
(20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM
dithiothreitol, 0.1 mM EGTA, 0.1 mM EDTA, 0.5 mM phenyl-
methylsulfonyl fluoride, and 0.2 mM phenylmethylsulfonyl fluo-
ride, 0.5% Nonidet P-40). The cells were lysed, followed by
centrifugation at 17006 g for 10 min. After separation of the
cytoplasmic fraction, nuclei were washed once with Buffer A and
resuspended in ice-cold buffer B (10 mM HEPES, pH 7.9, 25%
glycerol, 1.5 mM MgCl2 and 0.4 mM NaCl, 1 mM dithiothreitol,
and 0.2 mM phenylmethylsulfonyl fluoride). After 1 h incubation
on ice and a centrifuge to clear the cellular debris, the nuclear
extracts were collected and used for immunoblotting.
Transient transfection
Transient transfection of cells was performed using LipofectA-
MINE-2000 or LipofectAMINE-PLUS (Invitrogene) as per the
manufacturer’s instructions.
Immunoprecipitation and immunoblotting
Immunoblotting and immunoprecipitation was performed as
described [24]. Briefly, 500 mg of cell lysates were incubated with
1 mg of primary antibody at 4uC for 3 h. Then, 20 mL of protein
A/G PLUS agarose beads was added and the incubation
continued overnight. The beads were washed and boiled in
SDS-PAGE loading buffer for 5 minutes before electrophoresis.
GST pull-down assay
GST pull-down assay was performed as described [24].
Bacterial cells were lysed using the following buffer: 20 mmol/L
Tris-Cl, 150 mmol/L NaCl, 2 mmol/L EDTA, 0.5% NP40,
pH 7.5. To determine the interaction between nCLU and pVHL,
bacterial lysates containing GST-nCLU were incubated with
glutathione-Sepharose 4B beads at 4uC for 1 h. The beads were
washed and incubated with bacterial cell lysates containing His-
pVHL, allowing the interaction between GST-nCLU and pVHL.
After washing, GST-nCLU and the bound pVHL were eluted
from the beads and subjected to electrophoresis.
In vitro ubiquitination assay
In vitro ubiquitination assay was performed as described [25]
and the Reaction II reticulocyte conjugation kit (Bostonbiochem,
MA) was employed in this assay. To isolate the pVHL complex,
Myc-VHL was transiently expressed in 293T cells and four
hundred micrograms of the cellular proteins were immunoprecip-
itated with 1 mg of Myc antibody at 4uC for 3 h. Twenty
microliters of protein A/G PLUS agarose beads were added and
the incubation continued at 4uC overnight. The beads were
washed for four times with RIPA buffer, followed by two washes
with buffer containing 50 mM Tris-HCl and 3 mM DTT,
pH 8.0. The agarose beads that contained purified pVHL
complex were suspended in a final reaction volume of 50 mL
containing ATP-regenerating buffer, 5 mg/mL ubiquitin, 1 mg/mL
GST-nCLU, 100 ng/mL ubiquitin aldehyde, MG132 (5 mM), and
16 mL of purified rabbit reticulocyte fraction II, and incubated at
37uC for 2 h. After reaction, the total proteins generated in the
ubiquitination reaction were analyzed by western-blot.
Statistical analysis
The data represent the mean 6 SD from three independent
experiments except where indicated. Statistical analysis was
performed using the unpaired two-tailed Student’s t-test. The
difference is considered significant when a P value is less than 0.05.
Results
pVHL interacts with nCLU
pVHL is an adaptor protein and binds to many proteins. We
determined whether pVHL had an interaction with sCLU and
nCLU. 293T cells were transiently transfected with HA-VHL plus
Myc-sCLU or HA-VHL plus Myc-nCLU plasmids. Immunopre-
cipitation was performed and the results indicated that HA-pVHL
co-immunoprecipitated with Myc-nCLU (Fig. 1A, Fig. S1A) but
not Myc-sCLU (Fig. 1A), indicating that pVHL had an interaction
with nCLU. We repeated the experiment in 293T cells to confirm
the interaction between pVHL and nCLU. The cells were
transfected with Myc-VHL and HA-nCLU vectors. The results
showed that Myc-pVHL and HA-nCLU also co-immunoprecip-
itated (Fig. 1B, Fig. S1B). A direct interaction between pVHL and
nCLU was ascertained by GST-pull down assays (Fig. 1C). These
results suggest that pVHL binds to nCLU directly.
We determined the domain of pVHL that nCLU might bind to.
pVHL contains two functional sub-domains termed a and b, and
the b domain (residues 63–155) functions for recognition of
substrate. GST-pull down assay was performed using pVHL
fragments covering different regions. VHL encodes wild-type
pVHL, VHL(1-155) encodes pVHL without a domain, and
VHL(D63-155) encodes pVHL without b domain. The results
showed that pVHL and pVHL(1-155) bound to nCLU (Fig. 1D).
However, pVHL(D63-155) had no interaction with nCLU. The
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nCLU might be a substrate of pVHL.
We next determined the site of nCLU that pVHL bound to.
Our results showed pVHL had no interaction with nCLU if the N-
terminal coil-coil domain of nCLU was deleted (Fig. 1E),
suggesting that this domain is required for nCLU-pVHL
interaction. sCLU also has the coil-coil domain, however, it does
not bind to pVHL (Fig. 1A). sCLU was translated from the first
ATG and nCLU was translated from the second ATG (Fig. 1E).
So, the N-terminal of sCLU is different from that of nCLU. This
might be the reason why nCLU binds to pVHL but sCLU does
not. This needs further investigation.
pVHL mediates ubiquitination of nCLU
pVHL functions as the substrate recognition component of an
E3-ubiquitin ligase that targets proteins for degradation. pVHL
interacted with nCLU (Fig. 1). Previous study demonstrated that
nCLU undergoes proteasomal degradation [26]. We therefore
tested whether pVHL mediated ubiquitination of nCLU. We
found that nCLU had polyubiquitination (Fig. 2A) and overex-
pression of VHL increased polyubiquitination of nCLU (Fig. 2B).
The identity of the band below IgG is unknown (Fig. 2A and B).
We determined whether pVHL promoted degradation of nCLU.
Unexpectedly, ectopic expression of VHL didn’t inhibit expression
of nCLU (Fig. 2C).
pVHL mediates K63-linked polyubiquitination of nCLU
It is known that, the K48-linked polyubiquitination leads to
protein proteasomal degradation and the K63-linked polyubiqui-
tination plays a role in protein trafficking, kinase and phosphatase
activation [27]. One of the examples is the non-degradative K63-
polyubiquitination of NEMO that leads to NF-kB activation [28].
This drove us to determine the kind of ubiquitination of nCLU
that pVHL mediated. We employed in our work two ubiquitin
mutants Ub(K48R) and Ub(K63R) where K48 or K63 was
mutated to arginine (R). 293T cells were transfected with nCLU,
VHL and Ub(K48R) or Ub(K63R) constructs. Overexpression of
VHL enhanced polyubiquitination of nCLU in the presence of
Ub(K48R) (Fig. 3A). However, overexpression of VHL had little
effect on the polyubiquitination of nCLU in the presence of
Ub(K63R) (Fig. 3A), implying that pVHL mediates K63-linked
ubiquitination of nCLU. Next, we employed a construct encoding
Ub(K63) in our experiments. Ub(K63) is the ubiquitin that the
lysine residues are mutated to R except K63. We found that
overexpression of VHL enhanced polyubiquitination of nCLU in
the presence of Ub(K63) (Fig. 3B). We also used a construct
encoding Ub(K48). All lysine residues of it are mutated to R except
Figure 1. pVHL binds to nCLU. (A) 293T cells were transfected as indicated. In 24 h, the cells were harvested and cellular proteins were prepared.
Immunoprecipitation was performed using HA antibody. (B) 293T cells were transfected with Myc-VHL and HA-nCLU. In 24 h, the cells were harvested
and immunoprecipitation was performed using HA antibody. (C) Direct interaction between nCLU and pVHL. Equal amount of bacterial lysates
containing His-pVHL were incubated with the glutathione-sepharose beads that already captured GST or GST-nCLU. The beads were washed and His-
pVHL retained on beads was determined by immunoblotting. CBB, Coomassie Blue Staining. (D) nCLU bound to pVHL at b domain. Equal amount of
bacterial lysates containing His-pVHL, His-pVHL(1-155) or His-pVHL(D63-155) were incubated with the glutathione-sepharose beads that already
captured GST or GST-nCLU. The beads were washed and His-pVHL or the truncated His-pVHL retained on beads was determined by immunoblotting.
(E) A various constructs encoding different nCLUs were designed. 293T cells were transfected with Myc-VHL and nCLU construct as indicated. 24 h
post-transfection, the cells were harvested for immunoprecipitation using HA antibody.
doi:10.1371/journal.pone.0035848.g001
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polyubiquitination of nCLU in the presence of Ub(K48) (Fig. 3C).
Taken together, these results suggest that pVHL mediates K63-
linked ubiquitination of nCLU.
The a domain of pVHL associates with the E3 ubiquitin ligase
complex [2]. We found that the ubiquitination of nCLU was
reduced significantly when VHL(1-155) was tested (Fig. 3D, Fig.
S2). Because pVHL(1-155) did not have a domain, the results
imply that the a domain of pVHL is required for pVHL to
mediate ubiquitination of nCLU. Moreover, expression of
VHL(D63-155) had little effect on ubiquitination of nCLU (Fig.
S2).
Next, we determined the effects of Rbx1, a subunit of the pVHL
E3 ubiquitin ligase complex, on K63-linked ubiquitination of
nCLU. We found that ectopic expression of Rbx1 enhanced K63-
linked ubiquitination of nCLU (Fig. 3E). We also determined
whether pVHL could mediate K63-linked polyubiquitination of
nCLU in vitro. The pVHL complex was isolated by immunopre-
cipitation and incubated with purified nCLU in Reaction II
Reticulocyte Conjugation Kit as described previously [25]. We
found that the isolated pVHL complex mediated K63-linked
ubiquitination of nCLU in vitro (Fig. 3F). However, the isolated
pVHL(1-155) could not mediate K63-linked ubiqitination of
nCLU in vitro. A control experiment was done. The results showed
that the ubiquitin chains were attached to GST-nCLU and not to
pVHL itself and Ub(K63R) was not linked to nCLU (Fig. S3).
Taken together, these results suggest that pVHL E3 ubiquitin
ligase complex mediates K63-linked ubiquitination of nCLU.
pVHL promotes nucleus localization of nCLU
It is believed that nCLU functions in nucleus. We therefore
asked whether the K63-linked ubiquitination promoted nuclear
translocation of nCLU. To know this, we determined the effect of
expression of Ub(K63) on cellular distribution of nCLU. We found
that ectopic expression of Ub(K63) enhanced nuclear localization
of nCLU (Fig. 4A). However, overexpression of Ub(K48) had little
effect on nCLU nuclear translocation. Immuno-staining of the
cells also indicated that ectopic expression of Ub(K63) enhanced
nuclear localization of nCLU (Fig. 4B). It was noted that
overexpression of Ub(K63)+nCLU, but not Ub(K48)+nCLU, led
to alteration of cell morphology (Fig. 4B). Taken together, these
results suggest that the K63-linked ubiquitination of nCLU
promotes nCLU nuclear translocation.
Next, we determined the effect of pVHL on nCLU nuclear
translocation. The nuclear and cytoplasmic proteins were isolated
and western-blot was performed. We found that overexpression of
pVHL enhanced protein levels of nCLU in nucleus (Fig. 4C).
Immuno-staining of the cells was also performed to indicate nCLU
distribution in cells. We found that Myc-nCLU proteins were
mainly cytoplasmic when the cells were transfected with Myc-
nCLU alone (Fig. 4D). If Myc-nCLU were co-transfected with
HA-VHL, the Myc-nCLU proteins in nucleus were increased.
These results suggest that pVHL promotes nuclear translocation of
nCLU. We noted that expression of exogenous VHL+nCLU
altered cell morphology (Fig. 4D). This is similar to the results of
Fig. 4B. The altered cell morphology might be due to increased
nCLU in nucleus.
Discussion
It is known that pVHL targets HIFa for proteasomal
degradation. As an adaptor protein, pVHL not only binds to
HIFa but also binds to many other proteins and has multiple
functions [1]. We found in our work that pVHL bound to nCLU
and mediated nCLU K63-linked ubiquitination, which may lead
to nuclear translocation of nCLU. To our knowledge, this is the
first report to demonstrate that pVHL mediates K63-linked
ubiquitination of a protein.
The addition of ubiquitin to proteins occurs through an
enzymatic cascade. Firstly, an activating enzyme, E1, is charged
with ubiquitin, then the ubiquitin is transferred to an E2-
conjugating enzyme and, finally, it is attached to a substrate by
an E3 ligase [29]. There are a few types of polyubiquitin chains
[27] and in many conditions the type of polyubiquitin chain
formed appears to be directed primarily by the cooperating E2
enzyme. E2 dictates the type of inter-ubiquitin linkages and
thereby determines the fate of the substrate [30]. We found that
pVHL mediated K63-linked ubiquitination of nCLU (Fig. 3) and
promoted nCLU nuclear translocation (Fig. 4). Our results suggest
that, for different substrates, pVHL may mediate different types of
ubiquitination, probably using different E2 enzymes.
Although protein ubiquitination has been best characterized as
a mechanism for targeting proteins to the proteasome for
degradation, recently it has become clear that this modification
can also serve many other functions. For example, K48-linked
ubiquitination tags the target protein to be degraded by the
Figure 2. pVHL mediates ubiquitination of nCLU. (A) Modification of nCLU by ubiquitin. 293T cells were transfected with indicated plasmids
and incubated for 24 h before harvest for immunoprecipitation and western-blot. (B) pVHL enhanced the ubiquitination of nCLU. 293T cells were
transfected with HA-Ub, Myc-nCLU and R-VHL plasmids. In 24 h, the cells were harvested and cellular proteins were prepared for
immunoprecipitation using HA antibody. (C) HCT116 and 293T cells were transfected with Myc-VHL. In 48 h, the cells were harvested and lysed.
Expression of nCLU was determined by western-blot.
doi:10.1371/journal.pone.0035848.g002
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indicator of subsequent lysosomal degradation [31]. During the
last few years the K63-ubiquitination has emerged as a novel post-
translational modification of remarkable functional interest for
fine-tuning signal transduction pathways [27,32]. We found that
ectopic expression of pVHL promoted nuclear translocation of
nCLU (Fig. 4). This might be one function of pVHL that mediates
K63-linked ubiquitination of nCLU. There are currently a few
examples of ubiquitin serving as a nuclear import signal. For
example, TRAF6, an E3 ubiquitin ligase, was shown to mediate
K63-linked ubiquitination of p75 cytoplasmic interactor (NRIF)
and this modification is necessary for NRIF nuclear translocation
[33].
nCLU has been found to trigger cell death when in nucleus in a
few systems [22]. However, we did not find that overexpression of
nCLU led to cell apoptosis in our work. The difference might be
due to different cells used in these works. It should be noted that in
our work the increased nucleus nCLU do altered the morphology
of these cell (Fig. 4B and D). The physiological function of pVHL
that mediates nCLU ubiquitination needs further investigation.
For example, it will be interesting to determine whether pVHL-
mediated ubiquitination and nucleus translocation of nCLU plays
an important role in regulation of cell proliferation and apoptosis.
Another important question is whether pVHL is required for
nCLU nucleus translocation.
In this manuscript, we have disclosed a novel function of pVHL
that mediates K63-linked ubiquitination and identified nCLU as a
new target of pVHL. These results indicate that pVHL mediates
not only K48- but also K63-linked ubiquitination of proteins. It is
known that K48-linked ubiquitination usually leads to protein
degradation and K63-linked ubiquitination functions as a post-
translational modification for protein trafficking and fine-tuning
signal transduction pathways. Our results may provide a new sight
of pVHL’s function.
Figure 3. pVHL mediates K63-linked ubiquitination of nCLU. (A) pVHL enhanced the K63-linked ubiquitination of nCLU. 293T cells were
transfected with Myc-nCLU, R-VHL and HA-Ub(K48R) (or Ub(K63R)). In 24 h, the cells were lysed and immunoprecipitation was done using HA
antibody. The relative amount of ubiquitinated nCLU was determined by densitometry assay. (B) pVHL enhanced the ubiquitination of nCLU in the
presence of Ub(K63). 293T cells were transfected with Myc-nCLU, R-VHL and HA-Ub(K63) plasmids. In 24 h, the cells were harvested and then lysed for
immunoprecipitation using HA antibody. (C) pVHL did not enhance nCLU ubiquitination in the presence of Ub(K48). 293T cells were transfected with
Myc-nCLU, R-VHL and HA-Ub(K48) plasmids. In 24 h, the cells were harvested and then lysed for immunoprecipitation using HA antibody. (D) pVHL(1-
155) did not mediate ubiquitination of nCLU. 293T cells were transfected with various constructs as indicated. In 24 h, the cell lysates were prepared
for immunoprecipitation and western-blot. (E) Overexpression of Rbx1 enhanced K63-linked ubiquitination of nCLU. 293T cells were transfected as
indicated. In 24 h, the cells were harvested and cell lysates were prepared for immunoprecipitation. The relative amount of ubiquitinated Myc-nCLU
was determined by densitometry assay. (F) pVHL mediated K63-linked ubiquitination of nCLU in vitro. In vitro ubiquitination assay was performed as
described under Methods.
doi:10.1371/journal.pone.0035848.g003
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Figure S1 (A) 293T cells were transfected with Myc-nCLU plus
empty vector or Myc-nCLU plus HA-VHL. In 24 h, the cells were
harvested and cellular proteins were prepared. Immunoprecipita-
tion was performed using HA antibody. The results of negative
control experiment showed that HA antibody did not interact with
Myc-tagged nCLU. (B) 293T cells were transfected as indicated. In
24 h, the cells were harvested and immunoprecipitation was
performed using HA antibody. The results of negative control
experiment indicated that the HA antibody did not interact with
Myc-tagged VHL.
(TIF)
Figure S2 pVHL(1-155) and pVHL(D63-155) had little
effect on ubiquitination of nCLU. 293T cells were transfected
with HA-nCLU, His-Ub and various Myc-VHL constructs as
indicated. In 24 h, the cells were harvested and cellular proteins
were prepared for immunoprecipitation and western-blot.
(TIF)
Figure S3 pVHL mediated K63-linked ubiquitination of
nCLU in vitro. In vitro ubiquitination of nCLU by pVHL was
performed as described under Methods. Ubiquitin or Ub(K63R)
at 5 mg/mL was added to the reaction system.
(TIF)
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